Form 8-K Intellia Therapeutics, For: Aug 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Intellia Therapeutics (NTLA) PT Lowered to $54 at RBC Capital
August 9, 2024 6:27 AM EDTRBC Capital analyst Luca Issi lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $54.00 (from $60.00) while maintaining a Outperform rating.
The analyst comments "Following Phase II study that hit primary and all secondary endpoints (to be presented in 4Q) NTLA is planning to start... More
